文献速递产科母胎医学

对产前识别的高概率病例进行脐带血产后基因检测

Postnatal genetic testing on cord blood for prenatally identified high-probability cases.
PubMed 文献 · Prenat Diagn · 2023-04-18

研究评估脐带血产后基因检测对产前识别的高概率胎儿的效用,2016至2021年间在两家医院纳入448名符合标准者,393份样本完成分析,92名新生儿获得遗传学诊断,平均检测时间10.3天,68例诊断可能影响新生儿管理。

要点

  • 产前识别高概率胎儿并对脐带血进行基因检测有助于及时遗传诊断和新生儿管理。
  • 448名同意检测者中,393份(87.7%)样本完成分析,92名(23.4%)新生儿获得诊断。
  • 仅1.4%(6/418)样本无法明确排除母体细胞污染(MCC)。

核心结论

  • 产前识别高概率胎儿并对脐带血进行基因检测有助于及时遗传诊断和新生儿管理,为高概率新生儿提供 reassurance 并减少产后诊断的漫长过程。

研究设计与样本

  • 研究纳入2016至2021年间在布莱根妇女医院和爱默生医院符合以下任一标准者:胎儿异常、cfDNA或生化分析无创产前筛查阳性、或家族史;也包括社会指南推荐但未做微阵列而需诊断性检测者。
  • 448名个体同意脐带血检测,其中370名(82.6%)因胎儿异常,51名(11.4%)因高概率cfDNA,27名(6.0%)因家族史;共393份(87.7%)样本完成分析。

主要发现

  • 遗传检测通过核型分析(n=37)、染色体微阵列(CMA)(n=32)和其他分子分析(n=23)在92名(23.4%)新生儿中得出诊断。
  • 检测平均耗时10.3天(范围1-118天)。
  • 68例(73.9%)诊断可能影响新生儿管理。
  • 仅1.4%(6/418)样本无法明确排除母体细胞污染(MCC)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the utility of postnatal genetic testing on umbilical cord blood (CB) for prenatally identified high-probability fetuses. METHOD: CB for genetic testing was offered to individuals who met one of the following criteria: (i) fetal anomaly, (ii) positive non-invasive prenatal screening by cfDNA or biochemical analysis, or (iii) family history. Individuals with diagnostic testing, but not microarray, were also included when recommended by society guidelines. CB was collected at Brigham and Women's and Emerson Hospitals between 2016 and 2021. RESULTS: 448 individuals consented for cord blood testing (370 (82.6%) for fetal anomalies, 51 (11.4%) for high-probability cfDNA, and 27 (6.0%) for family history) and a total of 393 (87.7%) samples were analyzed. Genetic testing yielded a diagnosis in 92 (23.4%) neonates by karyotype (n = 37), chromosomal microarray (CMA) (n = 32), and other molecular analysis (n = 23). Testing averaged 10.3 days (range 1-118 days). 68 (73.9%) diagnoses potentially impacted neonatal management. MCC could not be definitively excluded in only 1.4% (6/418) of samples. CONCLUSION: Prenatal identification of high-probability fetuses and genetic testing on CB facilitates timely genetic diagnoses and neonatal management. Testing provides reassurance and reduces a postnatal diagnostic odyssey for high-probability neonates.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Adams S, Llorin H, Dobson LJ, et al. Postnatal genetic testing on cord blood for prenatally identified high-probability cases. Prenat Diagn. 2023. PMID: 37036331. doi:10.1002/pd.6352

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。